Yoshihiko Sakata

624 total citations
29 papers, 315 citations indexed

About

Yoshihiko Sakata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yoshihiko Sakata has authored 29 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Yoshihiko Sakata's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Yoshihiko Sakata is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Yoshihiko Sakata collaborates with scholars based in Japan. Yoshihiko Sakata's co-authors include Kazuya Ichikado, Kodai Kawamura, Yuko Yasuda, Keisuke Anan, Aiko Nakano, Kenichi Suzuki, Noriyuki Saito, T. Toyota, Takuro Sakagami and Moritaka Suga and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Yoshihiko Sakata

26 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshihiko Sakata Japan 12 169 146 79 34 32 29 315
Shuanying Yang China 10 62 0.4× 79 0.5× 150 1.9× 38 1.1× 14 0.4× 22 312
Xiaoyu Ma China 13 71 0.4× 56 0.4× 152 1.9× 9 0.3× 21 0.7× 38 382
Paola Venturino Italy 10 140 0.8× 230 1.6× 65 0.8× 10 0.3× 49 1.5× 15 376
Johan Willemse Belgium 11 54 0.3× 62 0.4× 91 1.2× 11 0.3× 19 0.6× 18 333
Chao‐Yuan Chang Taiwan 11 61 0.4× 62 0.4× 137 1.7× 10 0.3× 11 0.3× 26 279
Hisahide Nishio Japan 13 121 0.7× 66 0.5× 154 1.9× 16 0.5× 43 1.3× 29 387
Zhiming Huang China 9 26 0.2× 99 0.7× 140 1.8× 18 0.5× 23 0.7× 13 349
D. G. McLeod United States 8 201 1.2× 65 0.4× 130 1.6× 39 1.1× 10 0.3× 12 383

Countries citing papers authored by Yoshihiko Sakata

Since Specialization
Citations

This map shows the geographic impact of Yoshihiko Sakata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihiko Sakata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihiko Sakata more than expected).

Fields of papers citing papers by Yoshihiko Sakata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshihiko Sakata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihiko Sakata. The network helps show where Yoshihiko Sakata may publish in the future.

Co-authorship network of co-authors of Yoshihiko Sakata

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshihiko Sakata. A scholar is included among the top collaborators of Yoshihiko Sakata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshihiko Sakata. Yoshihiko Sakata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abe, Masahiko, Kenta Murotani, Yuki Sato, et al.. (2025). A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 43(16_suppl). 12006–12006. 1 indexed citations
2.
Saruwatari, Koichi, Takaaki Tokito, Yoshihiko Sakata, et al.. (2025). Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer. Lung Cancer. 204. 108578–108578.
3.
4.
Kawachi, Hayato, Motohiro Tamiya, Yoshihiko Taniguchi, et al.. (2022). Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. JTO Clinical and Research Reports. 3(7). 100355–100355. 10 indexed citations
5.
Ichikado, Kazuya, Kodai Kawamura, Takeshi Johkoh, et al.. (2021). Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia. Scientific Reports. 11(1). 20051–20051. 2 indexed citations
6.
Sakata, Yoshihiko, Kodai Kawamura, Kazuya Ichikado, et al.. (2019). Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer. 10(12). 2259–2266. 20 indexed citations
7.
8.
Sakata, Yoshihiko, Kodai Kawamura, Yuko Yasuda, et al.. (2018). The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events. Asia-Pacific Journal of Clinical Oncology. 16(2). e113–e117. 11 indexed citations
9.
Sakata, Yoshihiko, et al.. (2017). Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease. BMC Pulmonary Medicine. 17(1). 173–173. 11 indexed citations
10.
Kawamura, Kodai, Kazuya Ichikado, Yoshihiko Sakata, et al.. (2016). Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. SpringerPlus. 5(1). 1193–1193. 25 indexed citations
11.
12.
Sakata, Yoshihiko, Kodai Kawamura, Kazuya Ichikado, Moritaka Suga, & Masakazu Yoshioka. (2013). Hermansky–Pudlak syndrome type 4 with interstitial pneumonia. Respiratory Medicine Case Reports. 9. 38–41. 9 indexed citations
13.
Sakata, Yoshihiko, et al.. (2002). Novel potent antagonists of human neuropeptide Y Y5 receptor. Part 1: 2-oxobenzothiazolin-3-acetic acid derivatives. Bioorganic & Medicinal Chemistry Letters. 12(8). 1171–1175. 10 indexed citations
14.
Sakata, Yoshihiko, et al.. (2002). Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors. Part 3: 7-Methoxy-1-hydroxy-1-substituted Tetraline Derivatives. Bioorganic & Medicinal Chemistry Letters. 12(5). 799–802. 14 indexed citations
15.
Sakata, Yoshihiko, et al.. (2002). Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives. Bioorganic & Medicinal Chemistry Letters. 12(5). 757–761. 12 indexed citations
16.
Motoyama, Yukio, et al.. (1995). Effect of TFC-612, a 7-thia prostaglandin E1 derivative, on a peripheral arterial occlusive disease model in rats. Prostaglandins. 49(3). 175–182. 3 indexed citations
17.
Sakata, Yoshihiko, Jiro Seki, Akito Tanaka, et al.. (1993). The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. European Journal of Pharmacology. 243(2). 179–184. 18 indexed citations
18.
Motoyama, Yukio, et al.. (1992). TFC-612, a prostaglandin E1 derivative, enhances fibrinolytic activity in rats. Thrombosis Research. 65(1). 55–63. 3 indexed citations
19.
Motoyama, Yukio, et al.. (1991). The effects of TFC-612, a 7-thia prostaglandin E1 derivative, on platelet function. Thrombosis Research. 62(5). 471–480. 5 indexed citations
20.
Suzuki, Kenichi, Noriyuki Saito, Yoshihiko Sakata, T. Toyota, & Y Goto. (1990). A new prostaglandin E1 analogue (TFC-612) improves the reduction in motor nerve conduction velocity in spontaneously diabetic GK (Goto-Kakizaki) rats. Prostaglandins. 40(5). 463–471. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuanying Yang Breakdown of academic impact, for papers by Xiaoyu Ma Breakdown of academic impact, for papers by Paola Venturino Breakdown of academic impact, for papers by Johan Willemse Breakdown of academic impact, for papers by Chao‐Yuan Chang Breakdown of academic impact, for papers by Hisahide Nishio Breakdown of academic impact, for papers by Zhiming Huang Breakdown of academic impact, for papers by D. G. McLeod
Rankless by CCL
2026